In last trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 12.29 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $1.74 trading at -$0.04 or -2.25% at ring of the bell on the day assigns it a market valuation of $581.04M. That closing price of IOVA’s stock is at a discount of -618.97% from its 52-week high price of $12.51 and is indicating a premium of 5.75% from its 52-week low price of $1.64. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 10.46 million shares which gives us an average trading volume of 13.44 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Upright in the red during last session for losing -2.25%, in the last five days IOVA remained trading in the red while hitting it’s week-highest on Friday, 06/20/25 when the stock touched $1.74 price level, adding 16.67% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -78.68% in year-to-date performance and have moved -14.71% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of 0.58% in past 30-days. Number of shares sold short was 90.96 million shares which calculate 6.77 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 56.5% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -14.94% in reaching the projected high whereas dropping to the targeted low would mean a loss of -14.94% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.17% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 12.10% while estimates for its earnings growth in next 5 years are of 44.97%.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.48% of company’s total shares while institution are holding 81.25 percent of that, with stock having share float percentage of 81.64%. Investors also watch the number of corporate investors in a company very closely, which is 81.25% institutions for Iovance Biotherapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.1113 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1052 of outstanding shares, having a total worth of $207.98 million.
